Persistent Asset Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-241
Closed -$32.5K 211
2025
Q1
$32.5K Buy
+241
New +$2.46K 0.03% 143

Other funds holding KALV

Persistent Asset Partners's KALV Position: Q2 2026 in Review

Persistent Asset Partners sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 9,001 shares — an estimated $181K sold.

Persistent Asset Partners first reported a position in KALV in Q4 2024 and held it in 3 quarters. The position peaked at $393K in Q1 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Persistent Asset Partners reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 9,001 KalVista Pharmaceuticals shares in Q2 2026, an estimated $181K.
  • Persistent Asset Partners first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Persistent Asset Partners's KalVista Pharmaceuticals position peaked at $393K in Q1 2025.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.